Naturally occurring IgM anti-leukocyte autoantibodies inhibit T-cell activation and chemotaxis.
BACKGROUND
Naturally occurring IgM antileukocyte autoantibodies (IgM-ALA) are present from birth and increase during inflammatory processes of diverse etiologies. The clinical observation demonstrating a significant correlation (P < 01) between lack of acute rejections and presence of high levels of IgM-ALA in recipients of kidney allografts prompted us to study if IgM-ALA alters T-cell function and leukocyte chemotaxis.


METHODS
In-vitro functional assays were performed using leucocytes isolated from human peripheral blood. In-vivo studies were performed in C57BL6 mice.


RESULTS
Human studies revealed that IgM-ALA consist of several different IgM, each with specificities for a different leukocyte receptor, e.g., CD3, CD4, CCR5, and CXCR4. We show that IgM inhibits T-cell activation, proliferation, and chemotaxis. Data on in vivo murine models of ischemia-reperfusion injury and cardiac transplantation support our hypothesis.


CONCLUSIONS
The innate anti-inflammatory mechanism of IgM-ALA can be exploited by using purified normal IgM to inhibit inflammatory states or by a vaccine approach to increase in vivo production of IgM-ALA (e.g., prior to a transplant).
Lobo
Peter I
PI
Center for Immunity, Inflammation and Regenerative Medicine, University of Virginia, Charlottesville, VA 22908, USA. pil@virginia.edu
Schlegal
Kailo H
KH
Vengal
John
J
Okusa
Mark D
MD
Pei
Hong
H
D000818:Animals; D001323:Autoantibodies / Q000276:immunology / Q000494:pharmacology*; D016175:B-Lymphocyte Subsets / Q000276:immunology; D002455:Cell Division / Q000187:drug effects; D002464:Cell Migration Inhibition / Q000187:drug effects*; D005312:Fetal Blood / Q000166:cytology; D015483:HIV Antibodies / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology*; D007231:Infant, Newborn; D007676:Kidney Failure, Chronic / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology; D007962:Leukocytes / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008222:Lymphokines / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D010766:Phosphorylation / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D011971:Receptors, Immunologic / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000378:metabolism
D001323:Autoantibodies; D015483:HIV Antibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008222:Lymphokines; D011971:Receptors, Immunologic; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human
Curr Pharm Des. 2003;9(3):221-31
12570827
J Immunol. 2008 Feb 1;180(3):1780-91
18209075
Transplantation. 1999 Dec 27;68(12):1855-8
10628764
N Engl J Med. 2006 Mar 16;354(11):1166-76
16540617
Immunol Rev. 1986 Oct;93:53-79
3096878
Am J Med. 1985 Apr;78(4):621-6
2984932
N Engl J Med. 1970 Oct 1;283(14):724-8
5311527
Lancet. 1978 Jun 10;1(8076):1228-9
77994
J Clin Invest. 1997 May 15;99(10):2488-501
9153293
Science. 2000 Oct 6;290(5489):89-92
11021805
Proc Clin Dial Transplant Forum. 1977;7:4-6
356038
J Immunol Methods. 1998 Jul 1;216(1-2):117-37
9760219
J Reprod Immunol. 1995 May;29(1):61-7
8531192
Arch Intern Med. 1989 Aug;149(8):1833-5
2504122
AIDS. 1991 Mar;5(3):345-6
2059381
J Clin Lab Immunol. 1979 Feb;1(4):283-8
387963
Transplantation. 1981 Sep;32(3):233-7
7025372
Scand J Immunol. 1994 Jul;40(1):77-82
7913247
Arthritis Rheum. 1975 Jan-Feb;18(1):1-8
46753
Immunol Rev. 2001 Aug;182:18-32
11722621